DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» MEK inhibitor
MEK inhibitor
BRAF Inhibitors Amplify the Proapoptotic Activity of MEK
Combined BRAF and MEK Inhibition with Vemurafenib and Cobimetinib for Patients with Advanced Melanoma
Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event Evaluation
Mekinist Tablets
BRAF-MEK Inhibitor Combo Approved for Adjuvant Melanoma Therapy
RASA1/NF1 Mutant Lung Cancer: Racing to the Clinic? Shunsuke Kitajima1 and David A
Advances in Targeted Therapy for Melanoma: a Focus on MEK Inhibition
Response To: 'Efficacy and Improved Tolerability of Combination Therapy
Targeting Epha2 in Cancer Ta Xiao1, Yuhang Xiao2, Wenxiang Wang3,4, Yan Yan Tang4, Zhiqiang Xiao2* and Min Su3,4*
BRAF Gene and Melanoma: Back to the Future
MEKINIST (Trametinib) Label Snda 204114 S-001
Selumetinib (Koselugo™) EOCCO POLICY
MEK Inhibitors for the Treatment of Non-Small Cell Lung Cancer
Unraveling the Role of the Immune System in BRAF–MEK Inhibitor Responses Keiran S.M
Systemic MEK Inhibition Enhances the Efficacy of 5-Aminolevulinic Acid
Ocular Changes in Metastatic Melanoma Patients Treated with MEK Inhibitor Cobimetinib and BRAF Inhibitor Vemurafenib
210496Orig1s000
The MEK Inhibitor Selumetinib Complements CTLA-4 Blockade By
Top View
Thyroid Cancer That No Longer Responds to Radioactive Iodine May Become Sensitive After Starting Anti-Cancer Drugs
BRAF Inhibitors and Radiation Do Not Act Synergistically to Inhibit WT and V600E BRAF Human Melanoma LISA WALTER and LUCIE HEINZERLING
Intracranial Antitumor Activity with Encorafenib Plus Binimetinib in Patients with Melanoma Brain Metastases: a Case Series
Reduced MEK Inhibition Preserves Genomic Stability in Naive Human Embryonic Stem Cells
A Novel Combined Targeted Therapy with Bromodomain Antagonist and MEK Inhibitor in Anaplastic Thyroid Cancer
MEKINIST (Trametinib) Tablets Are Supplied As 0.5 Mg and 2 Mg Tablets for Oral Administration
Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination with MEK Inhibitors for Metastatic Melanoma
ONO Receives Approval of BRAFTOVI® Capsule, a BRAF Inhibitor And
Targeting Alterations in the RAF–MEK Pathway
Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations Or Fusions: Results from NCI-MATCH (EAY131) Douglas B
BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
BRAF Mutant Non-Small Cell Lung Cancer and Treatment with BRAF Inhibitors
Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity
Annrheumdis-2019-216610.Full.Pdf
Severe Epistaxis Secondary to Dabrafenib and Trametinib Toxicity in Non-Small Cell Lung Carcinoma with Small Bowel Metastasis
Resistance to Molecularly Targeted Therapies in Melanoma
The Basis for Rational Combination Using MEK Inhibitors in KRAS-Mutant Cancers Shunsuke Okumura and Pasi A
5.01.589 BRAF and MEK Inhibitors
Corporate Medical Policy BRAF Gene Mutation Testing to Select Melanoma Or Glioma Patients for Targeted Therapy
Overcoming Acquired BRAF Inhibitor Resistance in Melanoma Via Targeted Inhibition of Hsp90 with Ganetespib
Novel ATP-Competitive MEK Inhibitor E6201 Is Effective Against Vemurafenib-Resistant Melanoma Harboring the MEK1-C121S Mutation in a Preclinical Model
210496Orig1s000
Immunotherapy Or Molecularly Targeted Therapy: What Is the Best Initial Treatment for Stage IV BRAF-Mutant Melanoma? Geoffrey T
Current Development Status of MEK Inhibitors
New Drug Combination Strategies in Melanoma
MEK Inhibitors: KE Duncan , LY Chang and M Patronas REVIEW a New Class of Chemotherapeutic Agents with Ocular Toxicity
MEK Inhibitors in Non-V600 BRAF Mutations and Fusions
Phase II Trial to Evaluate Trametinib in Patients with Advanced NF1-Mutant Non-Small Cell Lung Cancer
Impact of MEK Inhibitor Therapy on Neurocognition in Neurofibromatosis Type 1
Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: a University of Chicago Phase II Consortium Trial
Current Insights Into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade
MEK Inhibitor Selumetinib (AZD6244; ARRY-142886)
Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future